HLS – Morgans rates the stock as Hold

Healius provided a trading update, expecting to report FY20 underlying earnings (EBIT) of $102m-$104m and underlying profit (NPAT) of $54m-56m. Morgans states that covid-19 impacts were seen across all segments, with Imaging and Day Hospitals/IVF faring the worst, while Pathology did better as covid-19 testing helped buffer declines across base testing.

Read More